Allotera Therapeutics
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) (NCT06514794) | Allotera Therapeutics | 2025-01-31 |
| A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (NCT05674526) | Allotera Therapeutics | 2024-05-21 |
| A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (NCT05470140) | Allotera Therapeutics | 2023-07-01 |
| A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 (NCT05509855) | Allotera Therapeutics | 2022-08-22 |
| A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (NCT04984356) | Allotera Therapeutics | 2022-01-14 |
Track Allotera Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.